Sanofi v. Watson Laboratories Inc.


(United States Federal Circuit) – Affirming the district court’s rulings in the case of a patent infringement claim relating to cardiovascular drugs where the court held that the plaintiff had proven that the defense’s sale of proposed generic drugs with their proposed labels would induce physicians to infringe, and holding that none of the patents were invalid for obviousness.